SIGHT SCIENCES INC (SGHT) Stock Price, Forecast & Analysis

USA • Nasdaq • NASDAQ:SGHT • US82657M1053

5.96 USD
-0.16 (-2.61%)
Last: Feb 5, 2026, 12:30 PM

SGHT Key Statistics, Chart & Performance

Key Statistics
Market Cap315.11M
Revenue(TTM)76.05M
Net Income(TTM)-46.11M
Shares52.87M
Float41.82M
52 Week High9.24
52 Week Low2.03
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.9
PEN/A
Fwd PEN/A
Earnings (Next)05-06
IPO2021-07-15
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
SGHT short term performance overview.The bars show the price performance of SGHT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40

SGHT long term performance overview.The bars show the price performance of SGHT in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 50 100

The current stock price of SGHT is 5.96 USD. In the past month the price decreased by -18.07%. In the past year, price increased by 120.94%.

SIGHT SCIENCES INC / SGHT Daily stock chart

SGHT Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to SGHT. When comparing the yearly performance of all stocks, SGHT is one of the better performing stocks in the market, outperforming 94.48% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

SGHT Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to SGHT. The financial health of SGHT is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SGHT Financial Highlights

Over the last trailing twelve months SGHT reported a non-GAAP Earnings per Share(EPS) of -0.9. The EPS increased by 11.76% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -39.66%
ROE -71.72%
Debt/Equity 0.62
Chartmill High Growth Momentum
EPS Q2Q%27.27%
Sales Q2Q%-1.25%
EPS 1Y (TTM)11.76%
Revenue 1Y (TTM)-4.39%

SGHT Forecast & Estimates

13 analysts have analysed SGHT and the average price target is 9.54 USD. This implies a price increase of 60.02% is expected in the next year compared to the current price of 5.96.

For the next year, analysts expect an EPS growth of 17.69% and a revenue growth -3.75% for SGHT


Analysts
Analysts76.92
Price Target9.54 (60.07%)
EPS Next Y17.69%
Revenue Next Year-3.75%

SGHT Ownership

Ownership
Inst Owners49.61%
Ins Owners18.82%
Short Float %2.77%
Short Ratio4.2

SGHT Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABT ABBOTT LABORATORIES19.08188.146B
ISRG INTUITIVE SURGICAL INC48.69169.625B
SYK STRYKER CORP24.19137.924B
BSX BOSTON SCIENTIFIC CORP22.29111.924B
BDX BECTON DICKINSON AND CO13.7559.33B
IDXX IDEXX LABORATORIES INC43.7951.339B
EW EDWARDS LIFESCIENCES CORP26.5846.291B
RMD RESMED INC21.8238.394B
GEHC GE HEALTHCARE TECHNOLOGY16.4737.64B
DXCM DEXCOM INC28.1327.621B

About SGHT

Company Profile

SGHT logo image Sight Sciences, Inc. is an ophthalmic medical device company, which focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company is headquartered in Menlo Park, California and currently employs 216 full-time employees. The company went IPO on 2021-07-15. The firm is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The firm operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.

Company Info

SIGHT SCIENCES INC

4040 Campbell Ave,, Suite 100

Menlo Park CALIFORNIA US

CEO: Paul Badawi

Employees: 216

SGHT Company Website

SGHT Investor Relations

Phone: 14158890550

SIGHT SCIENCES INC / SGHT FAQ

What does SGHT do?

Sight Sciences, Inc. is an ophthalmic medical device company, which focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company is headquartered in Menlo Park, California and currently employs 216 full-time employees. The company went IPO on 2021-07-15. The firm is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The firm operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.


Can you provide the latest stock price for SIGHT SCIENCES INC?

The current stock price of SGHT is 5.96 USD. The price decreased by -2.61% in the last trading session.


What is the dividend status of SIGHT SCIENCES INC?

SGHT does not pay a dividend.


What is the ChartMill technical and fundamental rating of SGHT stock?

SGHT has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What do analysts say about SIGHT SCIENCES INC (SGHT) stock?

13 analysts have analysed SGHT and the average price target is 9.54 USD. This implies a price increase of 60.02% is expected in the next year compared to the current price of 5.96.


What is SIGHT SCIENCES INC worth?

SIGHT SCIENCES INC (SGHT) has a market capitalization of 315.11M USD. This makes SGHT a Small Cap stock.


Can you provide the ownership details for SGHT stock?

You can find the ownership structure of SIGHT SCIENCES INC (SGHT) on the Ownership tab.